Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
SALT LAKE CITY, TORONTO & MONTRÉAL (May 8, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence. “Recursion has pioneered the massive, parallel generation of -omics data with […]
Cyclica’s MatchMaker™ complements DNA Encoded Library (DEL) experimental techniques for predicting drug discovery targets
This browser does not support PDF!
Cyclica to help expand Canadian platform for federated AI-powered insights in genomics and precision health
Toronto, Ontario — Today, a Canadian consortium, including Cyclica inc., (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, is announcing the launch of a new project to expand the development of a software platform to enable federated, AI-powered insights across networks of genomics and health data. The Canadian Platform […]
Dr. Vern de Biasi, Cyclica’s Chief Partnership Officer, interviewed by Maeil Business News, South Korea’s leading business newspaper
Read the full interview on Maeil Business News’ site.
Cyclica teams up with Uruguay national research agency, ANII, to enhance scientific innovation
09 March 2023, Toronto, Canada and Montevideo, Uruguay – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and the National Research and Innovation Agency (“Agencia Nacional de Investigación e Innovación” or ANII”), a Uruguayan government agency that funds and promotes research and innovation initiatives, announce a […]
U of T home to new hub that will strengthen Canada’s pandemic preparedness and increase biomanufacturing capacity (source: U of T)
This post was adapted from its original source and can be viewed here. A new national hub focused on enhancing Canada’s ability to respond quickly, effectively and equitably to future pandemics has become a reality with $2 million in funding from the Canada Biomedical Research Fund. Led and anchored by the University of Toronto, the Canadian […]
Cyclica’s 2022 Year in Review
Cyclica receives CAD$2.4M grant for a multi-targeted drug discovery program to advance non-hormonal contraceptive medicines
Cyclica receives a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to discover new therapeutic options for multiple low-data biological targets with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries. TORONTO, CANADA — November 15, 2022: Cyclica Inc., a neo-biotech […]
[White paper] Exploring the unexplored, drugging the undrugged: How Cyclica is opening new frontiers in drug discovery
Co-Development Agreement using AI Drug Discovery between Samjin Pharm. and Cyclica
Seoul, South Korea and Toronto, Canada – Samjin Pharmaceuticals Co., Ltd. (“Samjin”; CEO, Yong Ju Choi) a pharmaceutical company devoted to develop innovative drugs to treat diseases with high unmet medical needs, and Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance arobust and sustainable drug discovery pipeline announced today a co-development agreement for […]